ReviewJournal of cancer research and clinical oncology2004
A decade's studies on metastasis of hepatocellular carcinoma.
Review in Journal of cancer research and clinical oncology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 216 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
216 citing papers in PubMed, 5 syntheses or guidelines pooled it, 420 citations in OpenAlex.
- Prognostic value of osteopontin in patients with hepatocellular carcinoma: A systematic review and meta-analysis.Medicine · 2018Pooled it
- Overexpression of glypican-3 is a predictor of poor prognosis in hepatocellular carcinoma: An updated meta-analysis.Medicine · 2018Pooled it
- Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis.BMC cancer · 2014Pooled it
- Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis.PloS one · 2014Pooled it
- A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2013Pooled it
- Trial
- Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma.Oncotarget · 2015Trial
- Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors.Medical oncology (Northwood, London, England) · 2015Trial
- Trial
- Bioinformatics analysis of DLGAP5 as a biomarker in lung adenocarcinoma: implications for immune infiltration and targeted therapy.Discover oncology · 2025Article
- Mechanisms Involved in Focal Adhesion Signaling Regulating Tumor Anoikis Resistance.Cancer science · 2025Review
- Preoperative model for predicting early recurrence in hepatocellular carcinoma patients using radiomics and deep learning: A multicenter study.World journal of gastrointestinal oncology · 2025Article
- Review
- Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA.Hepatology international · 2023Article
- DLGAP5 promotes gallbladder cancer migration and tumor-associated macrophage M2 polarization by activating cAMP.Cancer immunology, immunotherapy : CII · 2023Article
- Effect of multiple peritumoral regions of interest ranges based on computed tomography radiomics for the prediction of early recurrence of hepatocellular carcinoma after resection.Quantitative imaging in medicine and surgery · 2023Article
- Lnc-PLA2G4A-4 facilitates the progression of hepatocellular carcinoma by inducing versican expression via sponging miR-23b-3p.Heliyon · 2023Article
- A multi-omics dataset of human transcriptome and proteome stable reference.Scientific data · 2023Article
- Phosphatase regenerating liver 3 participates in Integrinβ1/FAK-Src/MAPK signaling pathway and contributes to the regulation of malignant behaviors in hepatocellular carcinoma cells.Journal of gastrointestinal oncology · 2023Article
- Surgical treatment for recurrent hepatocellular carcinoma: Current status and challenges.World journal of gastrointestinal surgery · 2023Review
156 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastasis remains one of the major challenges before hepatocellular carcinoma (HCC) is finally conquered. This paper summarized a decade's studies on HCC metastasis at the Liver Cancer Institute of Fudan University. We have established a stepwise metastatic human HCC model system, which included a metastatic HCC model in nude mice (LCI-D20), a HCC cell line with high metastatic potential (MHCC97), a relatively low metastatic potential cell clone (MHCC97L) and several stepwise high metastatic potential cell clones (MHCC97H, HCCLM3, and HCCLM6) from their parent MHCC97 cell. Endeavors have been made for searching human HCC metastasis-related chromosomes/proteins/genes. Monogene-based studies revealed that HCC invasion/metastasis was similar to that of other solid tumors, and the biological characteristics of small HCC were only slightly better than that of large HCC. Using comparative genomic hybridization (CGH), fluorescence in situ hybridization (FISH), genotyping, cDNA microarray, and 2-dimensional gel electrophoresis, we obtained some interesting results. In particular, in collaboration with the National Institute of Health (NIH) in the United States, we generated a molecular signature that can classify metastatic HCC patients, identified osteopontin as a lead gene in the signature, and found that genes favoring metastasis progression were initiated in the primary tumors. We also found that chromosome 8p deletion, particularly in the region of 8p23, was associated with HCC metastasis. Cytokeratin 19 was identified as one of the proteins, which was found in MHCC97H, but not in MHCC97L cells. Experimental interventions using the high metastatic nude mice model have provided clues for the prevention of HCC metastasis. Translation from workbench to bedside demonstrated that serum VEGF, microvessel density, and p53 scoring may be of value for the prediction of postoperative metastatic recurrence. Interferon alpha proved effective for the prevention of recurrence both experimentally and clinically. In conclusion, HCC metastasis that probably initiated in the primary tumor is a multigene-involved, multistep, and changing process. The further elucidation of the mechanism underlying HCC metastasis will provide a more solid basis for the prediction and prevention of the metastatic recurrence of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.